Search in:

Advanced search

Biologics: Targets and Therapy Volume 3, 2009 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Review

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project

Kylie Thaler1 Department for Evidence-based Medicine and Clinical Epidemiology, Danube University Krems, Krems, AustriaCorrespondence[email protected]

Divya V Chandiramani2 UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Richard A Hansen2 UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Gerald Gartlehner1 Department for Evidence-based Medicine and Clinical Epidemiology, Danube University Krems, Krems, Austria

Pages 485-498 | Published online: 07 Dec 2022

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Appendix 1: References

FurstDEAdalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)J Rheumatol2003301225632567114719195
PubMed Web of Science ®Google Scholar
KeystoneECRadiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialArthritis Rheum20045051400141115146409
PubMed Web of Science ®Google Scholar
KimHYA randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexateAPLAR Journal of Rheumatology2007101916
Google Scholar
MiyasakaNClinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: The CHANGE studyMod Rheumatol200818325226218330677
PubMed Web of Science ®Google Scholar
van de PutteLBEfficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II studyAnn Rheum Dis200362121168117714644854
PubMed Web of Science ®Google Scholar
van de PutteLBEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnn Rheum Dis200463550851615082480
PubMed Web of Science ®Google Scholar
WeinblattMEAdalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialArthritis Rheum2003481354512528101
PubMed Web of Science ®Google Scholar
KlareskogLTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet2004363941067568115001324
PubMed Web of Science ®Google Scholar
LanJLA comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled studyJ Formos Med Assoc2004103861862315340661
PubMed Web of Science ®Google Scholar
MorelandLWTreatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion proteinN Engl J Med199733731411479219699
PubMed Web of Science ®Google Scholar
MorelandLWEtanercept therapy in rheumatoid arthritis. A randomized, controlled trialAnn Intern Med1999130647848610075615
PubMed Web of Science ®Google Scholar
MathiasSDHealth-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placeboClin Ther200022112813910688396
PubMed Web of Science ®Google Scholar
WeinblattMEA trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateN Engl J Med199934042532599920948
PubMed Web of Science ®Google Scholar
AbeTA multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritisJ Rheumatol2006331374416395748
PubMed Web of Science ®Google Scholar
KavanaughAChimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapyJ Rheumatol200027484185010782805
PubMed Web of Science ®Google Scholar
MainiRNTherapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis Rheum1998419155215639751087
PubMed Web of Science ®Google Scholar
MainiRInfliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupLancet199935491941932193910622295
PubMed Web of Science ®Google Scholar
WesthovensRThe safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trialArthritis Rheum20065441075108616572442
PubMed Web of Science ®Google Scholar
ZhangFCInfliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from ChinaAPLAR Journal of Rheumatology200692127130
Google Scholar

References

SaketkooLAEspinozaLRImpact of biologic agents on infectious diseasesInfect Dis Clin North Am2006204931961viii17118297
PubMed Web of Science ®Google Scholar
BurmesterGRMarietteXMontecuccoCAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trialAnn Rheum Dis200766673273917329305
PubMed Web of Science ®Google Scholar
ColombelJFLoftusEVJrTremaineWJThe safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patientsGastroenterology20041261193114699483
PubMed Web of Science ®Google Scholar
FleischmannRMSchechtmanJBennettRAnakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trialArthritis Rheum200348492793412687534
PubMed Web of Science ®Google Scholar
TesserJFleischmannRDoreRConcomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritisJ Rheumatol200431464965415088288
PubMed Web of Science ®Google Scholar
SchiffMHDiVittorioGTesserJThe safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditionsArthritis Rheum20045061752176015188350
PubMed Web of Science ®Google Scholar
SchaibleTFLong term safety of infliximabCan J Gastroenterol200014Suppl C29C32C
PubMedGoogle Scholar
LjungTKarlenPSchmidtDInfliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm CountyGut200453684985315138212
PubMed Web of Science ®Google Scholar
TakeuchiTTatsukiYNogamiYPostmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritisAnn Rheum Dis200867218919417644554
PubMed Web of Science ®Google Scholar
FleurenceRSpackmanECost-effectiveness of biologic agents for treatment of autoimmune disorders: Structured review of the literatureJournal of Rheumatology2006212417086602
PubMed Web of Science ®Google Scholar
GartlehnerGThiedaPMorganLCDrug Effectiveness Review Project: Targeted Immune ModulatorsPortlandOregon Health and Science UniversityIn press2009
Google Scholar
GrabowskiHCockburnILongGThe market for follow-on biologics: how will it evolve?Health Aff (Millwood)20062551291130116966725
PubMed Web of Science ®Google Scholar
RoosJCOstorAJTumor necrosis factor inhibitors for rheumatoid arthritisN Engl J Med20063551920462047 author reply 204817093259
PubMed Web of Science ®Google Scholar
KruegerGCallisKPotential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritisArch Dermatol (U S A)2004140218
PubMed Web of Science ®Google Scholar
NesbittAFossatiGBerginMMechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsInflamm Bowel Dis200713111323133217636564
PubMed Web of Science ®Google Scholar
ChitaleSMootsRAbatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritisExpert Opin Biol Ther20088111512218081541
PubMed Web of Science ®Google Scholar
KoHHBresslerBNatalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn’s diseaseExpert Rev Gastroenterol Hepatol200711293919072431
PubMedGoogle Scholar
SchunaAARituximab for the treatment of rheumatoid arthritisPharmacotherapy200727121702171018041890
PubMed Web of Science ®Google Scholar
NukiGBresnihanBBearMBMcCabeDLong-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trialArthritis Rheum200246112838284612428223
PubMed Web of Science ®Google Scholar
NixonRBansbackNBrennanAThe efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisonsRheumatology20074671140114717478472
PubMed Web of Science ®Google Scholar
HarrisRPHelfandMWoolfSHCurrent methods of the US Preventive Services Task Force: a review of the processAm J Prev Med2001203 Suppl213511306229
PubMed Web of Science ®Google Scholar
DeeksJJDinnesJD’AmicoREvaluating non-randomised intervention studiesHealth Technol Assess2003727iiix1173
PubMedGoogle Scholar
GartlehnerGHansenRANissmanDLohrKNCareyVA simple and valid tool distinguished efficacy from effectiveness studiesJ Clin Epidemiol200659101040104816980143
PubMed Web of Science ®Google Scholar
BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266
PubMed Web of Science ®Google Scholar
SongFAltmanDGGlennyAMDeeksJJValidity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBmj2003326738747212609941
PubMed Web of Science ®Google Scholar
SauriolLLaportaMEdwardesMDMeta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approachClin Ther200123694295611440294
PubMed Web of Science ®Google Scholar
BresnihanBAlvaro-GraciaJMCobbyMTreatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonistArthritis Rheum19984112219622049870876
PubMed Web of Science ®Google Scholar
CohenSHurdECushJTreatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum200246361462411920396
PubMed Web of Science ®Google Scholar
CohenSBMorelandLWCushJJA multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexateAnn Rheum Dis20046391062106815082469
PubMed Web of Science ®Google Scholar
GenoveseMCCohenSMorelandLCombination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis Rheum20045051412141915146410
PubMed Web of Science ®Google Scholar
US Food and Drug AdministrationCentre for Drug Evaluation and Research Drugs@FDA: Kineret 2009 [cited 2009 10th August]; URL: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.DrugDetails
Google Scholar
CohenSBMorelandLCushJJAnakinra (recombinant interleukin-1 receptor antagonist): a large, placebo controlled efficacy trial of anakinra in patients with erosive rheumatoid arthritis diseaseArthritis Rheum200144LB1
Google Scholar
FleischmannRMTesserJSchiffMHSafety of extended treatment with anakinra in patients with rheumatoid arthritisAnn Rheum Dis20066581006101216396977
PubMed Web of Science ®Google Scholar
ListingJStrangfeldAKarySInfections in patients with rheumatoid arthritis treated with biologic agentsArthritis Rheum200552113403341216255017
PubMed Web of Science ®Google Scholar
ZinkAListingJKarySTreatment continuation in patients receiving biological agents or conventional DMARD therapyAnn Rheum Dis20056491274127915708884
PubMed Web of Science ®Google Scholar
LangerHEMissler-KargerBKineret: eff icacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocolInt J Clin Pharmacol Res200323411912815224501
PubMedGoogle Scholar
SalliotCDougadosMGossecLRisk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnn Rheum Dis2009681253218203761
PubMed Web of Science ®Google Scholar
Humira^® (adalimumab) FDA label information URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf2008
Google Scholar
Kineret^® (anakinra) FDA label information URL http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/103950s5039lbl.pdf2004
Google Scholar
FDAEnbrel^® (etanercept) FDA label information URL http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf2009 [cited 2009; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf
Google Scholar
ClarkWJobanputraPBartonPBurlsAThe clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysisHealth Technol Assess2004818iiiivixx1105
Web of Science ®Google Scholar
MertensMSinghJAAnakinra for rheumatoid arthritisCochrane Database Syst Rev20091CD00512119160248
PubMed Web of Science ®Google Scholar
WailooABrennanABansbackNModeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare programAHRQ Technology Assessment Program2006
Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project

Appendix 1: References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project

Appendix 1: References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date